Study of Ro 205-2349 in Patients With Type 2 Diabetes Mellitus
NCT ID: NCT00057317
Last Updated: 2016-08-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
INTERVENTIONAL
2001-12-31
2003-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study to Determine the Efficacy, Safety, Tolerability & Pharmacokinetics of RO 205-2349 in Patients With Type 2 Diabetes Mellitus
NCT00057304
A Safety, Pharmacokinetics and Pharmacodynamics Study of RO6811135 in Patients With Type 2 Diabetes Mellitus
NCT01789788
A Study to Investigate in Healthy Volunteers (Part 1) and in Patients With Type 2 Diabetes Mellitus (Part 2) the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of RO6799477
NCT02164266
A Dose-Finding Study of RO4998452 in Patients With Diabetes Mellitus
NCT00800176
A Multiple Ascending Dose Study of R1511 in Patients With Type 2 Diabetes Mellitus.
NCT00517465
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ro 205-2349
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Type 2 diabetes for longer than 3 months
* HbA1c (glycosylated hemoglobin A1c) greater than 7.0% at screening
* FPG (fasting plasma glucose) greater than 126 mg/dL at screening
* BMI (body mass index) less than 40 kg/square meter
Exclusion Criteria
* Type 2 diabetes patients currently treated with insulin
* Type 2 diabetes patients currently or previously treated with Actos, Avandia or Rezulin
* FPG (fasting plasma glucose) greater than 270 mg/dL at baseline
* Impaired liver or kidney function
* Triglycerides greater than 600 mg/dL
* Uncontrolled hypertension
* Pregnant or lactating women
* Women not using adequate contraception
35 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hoffmann-La Roche
INDUSTRY
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Huntsville, Alabama, United States
Mesa, Arizona, United States
Scottsdale, Arizona, United States
Tucson, Arizona, United States
Tucson, Arizona, United States
Encino, California, United States
Fountain Valley, California, United States
Fremont, California, United States
Fresno, California, United States
Irvine, California, United States
Modesto, California, United States
Pasadena, California, United States
San Bruno, California, United States
Santa Rosa, California, United States
Sunnyvale, California, United States
Hamden, Connecticut, United States
Norwalk, Connecticut, United States
Newark, Delaware, United States
Hollywood, Florida, United States
Jacksonville, Florida, United States
Ocala, Florida, United States
West Palm Beach, Florida, United States
Atlanta, Georgia, United States
Lawrenceville, Georgia, United States
Honolulu, Hawaii, United States
Indianapolis, Indiana, United States
Overland Park, Kansas, United States
New Orleans, Louisiana, United States
Boston, Massachusetts, United States
Kansas City, Missouri, United States
St Louis, Missouri, United States
St Louis, Missouri, United States
Billings, Montana, United States
Omaha, Nebraska, United States
Las Vegas, Nevada, United States
Trenton, New Jersey, United States
Albuquerque, New Mexico, United States
Buffalo, New York, United States
New Hyde Park, New York, United States
Rochester, New York, United States
Charlotte, North Carolina, United States
Durham, North Carolina, United States
Greenville, North Carolina, United States
Morrisville, North Carolina, United States
Portland, Oregon, United States
Tualatin, Oregon, United States
Camp Hill, Pennsylvania, United States
Connellsville, Pennsylvania, United States
Philadelphia, Pennsylvania, United States
Philadelphia, Pennsylvania, United States
East Providence, Rhode Island, United States
Greer, South Carolina, United States
Memphis, Tennessee, United States
Dallas, Texas, United States
El Paso, Texas, United States
Houston, Texas, United States
Midland, Texas, United States
San Antonio, Texas, United States
San Antonio, Texas, United States
San Antonio, Texas, United States
Lebanon, Virginia, United States
Richmond, Virginia, United States
Virginia Beach, Virginia, United States
Edmonds, Washington, United States
Wenatchee, Washington, United States
Pleven, , Bulgaria
Plovdiv, , Bulgaria
Sofia, , Bulgaria
Sofia, , Bulgaria
Calgary, Alberta, Canada
Winnipeg, Manitoba, Canada
Halifax, Nova Scotia, Canada
Courtice, Ontario, Canada
Ottawa, Ontario, Canada
Windsor, Ontario, Canada
Laval, Quebec, Canada
Montreal, Quebec, Canada
Montreal, Quebec, Canada
Sainte-Foy, Quebec, Canada
Sherbrooke, Quebec, Canada
St. John's, , Canada
Tallinn, , Estonia
Tartu, , Estonia
Tartu, , Estonia
Võru, , Estonia
Ogre, , Latvia
Talsi, , Latvia
Tukums, , Latvia
Valmiera, , Latvia
Kaunas, , Lithuania
Kaunas, , Lithuania
Kaunas, , Lithuania
Vilnius, , Lithuania
Guadalajara, , Mexico
Guadalajara, , Mexico
Mexico City, , Mexico
Mexico City, , Mexico
Mexico City, , Mexico
Mérida, , Mexico
Monterrey, , Mexico
Monterrey, , Mexico
Monterrey, , Mexico
Pachuca, Hidalgo, , Mexico
Tijuana, , Mexico
Panama City, , Panama
Ponce, , Puerto Rico
Arad, , Romania
Brasov, , Romania
Bucharest, , Romania
Bucharest, , Romania
Galati, , Romania
Ploieşti, , Romania
Târgovişte, , Romania
Târgu Mureş, , Romania
Bracknell, , United Kingdom
Nottingham, , United Kingdom
Plymouth, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
WM16177
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.